VRTX250110P370000
- 0.46
- 0.000.00%
Vertex Pharmaceuticals Newsroom
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Vertex Grapples With Bearish Chart As Death Cross Emerges
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Vertex, Orna Therapeutics Collaborate on Gene Editing Therapies for Sickle Cell Disease, Beta Thalassemia
RBC Lifts Price Target on Vertex Pharmaceuticals to $401 From $400, Keeps Sector Perform Rating
Vertex Pharmaceuticals, Orna Therapeutics Announce Research Collaboration
Orna Therapeutics Enters Three-year Strategic Research Collaboration With Vertex Pharmaceuticals; Orna To Receive $65M Upfront Payment And Is Eligible To Receive Up To $635M Milestones
Express News | Vertex Pharmaceuticals Inc - Orna to Receive $65 Million Upfront, Eligible for up to $635 Million
Express News | Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (Scd) and Transfusion-Dependent Beta Thalassemia (Tdt)
Orna Therapeutics Establishes Strategic Collaboration With Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Bernstein Remains a Hold on Vertex Pharmaceuticals (VRTX)
Top Gap Ups and Downs on Monday: TSM, NVO, PG and More
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today